How to access Tezspire from Saudi Arabia — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient with severe asthma that remains inadequately controlled despite high-dose inhaled corticosteroids and a second controller may be evaluated by their treating pulmonologist or allergist for Tezspire (tezepelumab-ekko). Tezspire is FDA-approved in the United States and co-developed by AstraZeneca and Amgen. It is a first-in-class human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a cytokine upstream of multiple inflammation pathways — giving it efficacy across eosinophilic and non-eosinophilic severe asthma phenotypes. Where Tezspire is not on a Saudi hospital formulary for the patient's phenotype, a named-patient import pathway via the SFDA is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Tezspire is administered as a subcutaneous injection every 4 weeks. It is labeled as add-on maintenance therapy for severe asthma in patients 12 years and older, with no phenotype restriction. Your treating physician confirms asthma severity, exacerbation history, prior controller optimisation, and the monitoring plan per FDA labeling.
Is Tezspire legally importable into Saudi Arabia?
Yes — through the Saudi Food and Drug Authority (SFDA) named-patient / personal-use import framework. The pathway allows a Saudi-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
For severe asthma biologics, SFDA reviewers have a familiar submission pattern, and Tezspire-specific applications typically emphasise the phenotype-agnostic mechanism for patients for whom eosinophil-targeted biologics have not worked.
How the pathway works, step by step
- Consultation with your treating pulmonologist or allergist. Severity and exacerbation history documentation, phenotype assessment, and clinical rationale.
- Pre-treatment screening. Infection screening and baseline assessment per labeling.
- SFDA named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Cold-chain shipment. Tezspire ships at 2–8°C with continuous temperature monitoring.
- Arrival and first dose. The dispensing facility releases product for in-clinic or at-home administration after training — Tezspire is available as a pre-filled pen for self-administration in addition to the syringe.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming severe asthma, exacerbation history, prior controller regimen, phenotype notes, and Tezspire as the indicated add-on biologic
- Verification of their Saudi medical licence
- Patient identifier
- Pre-treatment screening confirmation
- Planned monthly dosing schedule
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for severe-asthma biologics.
Costs and timing
Tezspire's US cash-pay reference price for a single 210 mg pre-filled pen sits in a broad indicative range of roughly USD 3,500–4,000 per monthly dose. International cold-chain logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted. Maintenance doses ship on a rolling basis.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Tezspire specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for SFDA review.
- Logistics. Cold-chain, temperature-monitored shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient / personal-use framework with appropriate documentation.
How does Tezspire differ from other asthma biologics? Tezspire targets TSLP, an upstream cytokine that feeds multiple downstream inflammation pathways. It has shown efficacy across phenotypes, including in patients who do not have high eosinophil counts — which is often where other biologics are less useful.
Can Tezspire be self-injected? Yes, the pre-filled pen is designed for patient or caregiver self-injection after clinic training.
Will private insurance cover this? Cash-pay is the default. Some Saudi insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Tezspire coordination in Saudi Arabia.
Add me to the Tezspire waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.